









Mercado
/
Acciones
/
nasdaq-rgen
/

Repligen Corp

RGEN

142.180USD

+2.520+1.80%

Cierre 02/06, 16:00（ET）Cotizaciones retrasadas 15 min

8.00BCap. mercado

5096.06P/E TTM



Repligen Corp

142.180

+2.520+1.80%

Descripción general Finanzas Análisis Compañía

Descripción general

Finanzas

Análisis

Compañía

Más Datos de Repligen Corp Compañía

Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. Its focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. Its chromatography franchise includes several products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. Its TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes. Its desktop portfolio includes MAVERICK and MAVEN, REBEL, and ZipChip.

Información de Repligen Corp



Símbolo de cotizaciónRGEN

Nombre de la empresaRepligen Corp

Fecha de salida a bolsaApr 29, 1986

Director ejecutivoLoeillot (Olivier)

Número de empleados1778

Tipo de seguridadOrdinary Share

Fin del año fiscalApr 29

DirecciónBuilding 1, Suite 100

CiudadWALTHAM

Bolsa de valoresNASDAQ OMX - NASDAQ BASIC

PaísUnited States of America

Código postal02453

Teléfono17814499560

Sitio Webhttps://www.repligen.com/

Símbolo de cotizaciónRGEN

Fecha de salida a bolsaApr 29, 1986

Director ejecutivoLoeillot (Olivier)

Ejecutivos de Repligen Corp



Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Ms. Karen A. Dawes

Lead Independent Director

91.02K

-275.00%

Mr. Glenn P. Muir

Independent Director

35.92K

+3366.00%

Mr. Ralf Kuriyel

Senior Vice President - Research and Development

12.56K

+7478.00%

Mr. Olivier Loeillot

President, Chief Executive Officer, Director

6.02K

-7041.00%

Mr. Nicolas M. Barthelemy

Independent Director

4.94K

+973.00%

Mr. Rohin Mhatre, Ph.D.

Independent Director

3.32K

+973.00%

Mr. Tony John Hunt

Executive Chairman of the Board

Ms. Carrie Eglinton Manner

Independent Director

Mr. James R. Bylund

Chief Operating Officer

Dr. Konstantin Konstantinov, Ph.D.

Independent Director

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Ms. Karen A. Dawes

Lead Independent Director

91.02K

-275.00%

Mr. Glenn P. Muir

Independent Director

35.92K

+3366.00%

Mr. Ralf Kuriyel

Senior Vice President - Research and Development

12.56K

+7478.00%

Mr. Olivier Loeillot

President, Chief Executive Officer, Director

6.02K

-7041.00%

Mr. Nicolas M. Barthelemy

Independent Director

4.94K

+973.00%

Mr. Rohin Mhatre, Ph.D.

Independent Director

3.32K

+973.00%

Desglose de ingresos

Divisa: USDActualizado: mar., 6 de ene

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

La empresa aún no ha revelado los datos relevantes.

Por regiónUSD

Nombre

Ganancia

Proporción

North America

96.29M

51.00%

Europe

56.64M

30.00%

APAC/Other

35.87M

19.00%

Por negocio

Por región

La empresa aún no ha revelado los datos relevantes.

Estadísticas de accionistas

Actualizado: lun., 8 de dic

Accionistas

Tipos de accionistas

Accionistas

Proporción

The Vanguard Group, Inc.

8.85%

BlackRock Institutional Trust Company, N.A.

8.24%

T. Rowe Price Associates, Inc.

6.14%

Roy T. Eddleman UEO

5.88%

United Capital Financial Advisors, LLC

4.90%

Otro

65.99%

Accionistas

Proporción

The Vanguard Group, Inc.

8.85%

BlackRock Institutional Trust Company, N.A.

8.24%

T. Rowe Price Associates, Inc.

6.14%

Roy T. Eddleman UEO

5.88%

United Capital Financial Advisors, LLC

4.90%

Otro

65.99%

Tipos de accionistas

Accionistas

Proporción

Investment Advisor

60.03%

Investment Advisor/Hedge Fund

30.39%

Hedge Fund

15.72%

Individual Investor

6.35%

Research Firm

2.20%

Pension Fund

1.95%

Bank and Trust

1.82%

Sovereign Wealth Fund

0.60%

Family Office

0.50%

Participación institucional



Actualizado: jue., 1 de ene

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q4

1044

63.74M

113.23%

+2.55M

2025Q3

1027

55.23M

98.12%

-6.26M

2025Q2

1028

61.98M

110.32%

-3.21M

2025Q1

1054

62.91M

111.98%

-2.72M

2024Q4

1054

61.13M

109.11%

-3.76M

2024Q3

1046

60.75M

108.48%

-6.10M

2024Q2

1039

61.28M

109.67%

-2.73M

2024Q1

1036

60.56M

108.45%

-5.41M

2023Q4

1062

62.13M

111.29%

-2.30M

2023Q3

1063

61.47M

110.27%

+2.91M

Actividad de los accionistas



Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

The Vanguard Group, Inc.

5.03M

8.94%

-33.74K

-0.67%

Sep 30, 2025

BlackRock Institutional Trust Company, N.A.

4.64M

8.24%

-70.77K

-1.50%

Sep 30, 2025

T. Rowe Price Associates, Inc.

3.46M

6.14%

+27.66K

+0.81%

Sep 30, 2025

Roy T. Eddleman UEO

3.31M

5.88%

-67.50K

-2.00%

Dec 31, 2024

United Capital Financial Advisors, LLC

2.76M

4.9%

+2.76M

Sep 30, 2025

Fidelity Management & Research Company LLC

2.29M

4.08%

+930.01K

+68.16%

Sep 30, 2025

State Street Investment Management (US)

1.80M

3.2%

+178.91K

+11.03%

Sep 30, 2025

Citadel Advisors LLC

1.68M

2.99%

+621.66K

+58.48%

Sep 30, 2025

Point72 Asset Management, L.P.

1.44M

2.56%

-472.47K

-24.70%

Sep 30, 2025

Holocene Advisors, LP

1.38M

2.45%

+440.29K

+47.00%

Sep 30, 2025

ETFs relacionados



Actualizado: sáb., 6 de dic

Nombre

Proporción

First Trust NYSE Arca Biotechnology Index Fund

3.45%

Alger Mid Cap 40 ETF

3.1%

Congress SMid Growth ETF

2.46%

iShares Health Innovation Active ETF

2.28%

VanEck Biotech ETF

1.34%

Franklin Genomic Advancements ETF

1.23%

Pacer US Export Leaders ETF

1.18%

Alger 35 ETF

1.15%

WisdomTree BioRevolution Fund

1.06%

iShares Biotechnology ETF

0.7%

First Trust NYSE Arca Biotechnology Index Fund

Proporción3.45%

Alger Mid Cap 40 ETF

Proporción3.1%

Congress SMid Growth ETF

Proporción2.46%

iShares Health Innovation Active ETF

Proporción2.28%

VanEck Biotech ETF

Proporción1.34%

Franklin Genomic Advancements ETF

Proporción1.23%

Pacer US Export Leaders ETF

Proporción1.18%

Alger 35 ETF

Proporción1.15%

WisdomTree BioRevolution Fund

Proporción1.06%

iShares Biotechnology ETF

Proporción0.7%

Dividendos



Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Sin datos

División de acciones



Fecha

Fecha ex-dividendo

Tipo

Relación

Sin datos

Fecha

Fecha ex-dividendo

Tipo

Relación

Sin datos

KeyAI

